【摘要】：目的子宮內(nèi)膜癌因其逐年上升的發(fā)病率和年輕化趨勢而備受關(guān)注,深入研究其癌變機(jī)制,對于子宮內(nèi)膜癌的防治具有重要意義。本研究分析子宮內(nèi)膜樣腺癌、子宮內(nèi)膜不典型增生和子宮內(nèi)膜增生不伴非典型性內(nèi)膜中hMSH6和p56的表達(dá),探討hMSH6和p53在子宮內(nèi)膜癌變過程中的表達(dá)相關(guān)性及臨床意義。方法用免疫組化法檢測濱州醫(yī)學(xué)院附屬醫(yī)院病理科2010-08-01-2013-03-01刮宮及手術(shù)切除的65例子宮內(nèi)膜癌,15例子宮內(nèi)膜不典型增生及20例子宮內(nèi)膜增生不伴非典型性組織中p53和hMSH6的表達(dá)情況,統(tǒng)計學(xué)分析其表達(dá)水平與臨床病理因素之間的相關(guān)性。結(jié)果子宮內(nèi)膜樣腺癌組織hMSH6蛋白表達(dá)率為27.6%(18/65),明顯低于子宮內(nèi)膜不典型增生組織75.0%(15/20),及子宮內(nèi)膜增生不伴非典型性組織73.3%(11/15)。子宮內(nèi)膜樣腺癌組織p53蛋白表達(dá)率55.3%(36/65),明顯高于子宮內(nèi)膜不典型增生組織13.3%(2/15),及子宮內(nèi)膜增生不伴非典型性5.0%(1/20),其中子宮內(nèi)膜樣腺癌組hMSH6及p53的表達(dá)與子宮內(nèi)膜不典型增生組及子宮內(nèi)膜增生不伴非典型性組織相比差異有統(tǒng)計學(xué)意義(χ~2=10.99,P=0.002;χ~2=10.99,P=0.004),而子宮內(nèi)膜增生不伴非典型性組織與子宮內(nèi)膜不典型增生組相比差異無統(tǒng)計學(xué)意義,P0.05;hMSH6及p53蛋白的表達(dá)均與手術(shù)病理分期和組織學(xué)分級有關(guān),均P0.001。結(jié)論 hMSH6基因表達(dá)缺失及p53蛋白的表達(dá)與子宮內(nèi)膜癌的發(fā)生有關(guān),通過檢測兩者的表達(dá)水平可對子宮內(nèi)膜癌的早期預(yù)防,早期診斷提供重要依據(jù)。
[Abstract]:Objective endometrial carcinoma has attracted much attention because of its increasing incidence and young age. It is of great significance to study the carcinogenesis mechanism of endometrial carcinoma. In this study, the expression of hMSH6 and p56 in endometrioid adenocarcinoma, endometrial atypical hyperplasia and endometrial hyperplasia without atypical endometrium was analyzed, and the expression of hMSH6 and p53 in endometrial carcinogenesis was investigated. Methods Sixty-five cases of endometrial carcinoma were examined by immunohistochemical method in Department of Pathology, affiliated Hospital of Binzhou Medical College, 2010-08-01-2013-03-01 and surgically resected endometrial carcinoma. The expression of p53 and hMSH6 in 15 cases of endometrial atypical hyperplasia and 20 cases of endometrial hyperplasia without atypical tissue was analyzed statistically. Results the expression rate of hMSH6 protein in endometrial adenocarcinoma was 27.6% (18 / 65), which was significantly lower than that in endometrial atypical hyperplasia (75.0%). And endometrial hyperplasia without atypical tissue 73.3% (11 / 15). The expression rate of p53 protein in endometrial adenocarcinoma was 55.3% (36 / 65), which was significantly higher than that in atypical endometrial hyperplasia (13. 3%) and endometrial hyperplasia without atypical type (5. 0%) (1 / 20). The expression of hMSH6 and p53 in endometrioid adenocarcinoma group was significantly higher than that in atypical endometrial hyperplasia group and endometrial hyperplasia without atypical tissue (蠂 ~ 2 + 10.9% P0. 002). There was no significant difference between endometrial hyperplasia without atypical tissue and endometrial atypical hyperplasia (P 0.05). The expression of hMSH6 and p53 protein were related to the pathological stage and histological grade of operation (P 0.001). Conclusion the loss of hMSH6 gene expression and the expression of p53 protein are related to the occurrence of endometrial carcinoma. The detection of the expression level of both genes may provide important evidence for early prevention and early diagnosis of endometrial carcinoma.
【作者單位】： 濱州醫(yī)學(xué)院附屬醫(yī)院病理科;
【基金】：山東省自然科學(xué)基金(ZR2013HQ018) 煙臺市科技發(fā)展計劃(2013ZH098) 濱州市科技發(fā)展計劃(2014ZC0324)
【分類號】：R737.33

【相似文獻(xiàn)】

相關(guān)期刊論文 前7條

1 周琦,田桂蘭,肖覺,唐郢;子宮內(nèi)膜癌p53表達(dá)的臨床意義研究[J];腫瘤防治雜志;2003年08期

2 車耀潤,張朝,呂申,劉玲,王朝暉;子宮頸癌錯配修復(fù)基因產(chǎn)物與p53表達(dá)[J];中國腫瘤;2005年11期

3 劉召芬,程紅英,江森;子宮內(nèi)膜癌微衛(wèi)星不穩(wěn)定性和p53表達(dá)的臨床意義[J];浙江腫瘤;2000年04期

4 梁英;董穎;;子宮內(nèi)膜癌中c-myc與P53表達(dá)[J];內(nèi)蒙古醫(yī)學(xué)雜志;2008年07期

5 劉麗萍,孫麗君;卵巢癌化療中bcl-2,bax與p53表達(dá)的意義[J];遵義醫(yī)學(xué)院學(xué)報;2002年06期

6 羅瓊;邵少慰;劉曙光;雷斌;申洪;;宮頸病變Ki67和P53表達(dá)的定量分析及其臨床意義[J];中國體視學(xué)與圖像分析;2013年03期

7 ;[J];;年期

相關(guān)碩士學(xué)位論文 前3條

1 劉寧;子宮內(nèi)膜癌雌、孕激素受體、P53表達(dá)及意義[D];山東大學(xué);2010年

2 王培;子宮脫垂患者主韌帶組織中ER-α、β亞型和P53表達(dá)的關(guān)系及意義[D];河北醫(yī)科大學(xué);2013年

3 趙洪偉;宮頸癌中Ebp1與p53表達(dá)的相關(guān)性分析及臨床意義[D];延邊大學(xué);2014年

，

本文編號：2335015